RxDoctor Payments Data

Erica Gerstenmaier, PA

Physician Assistant · Akron, OHNPI 1588822639

Payments from drug & device makers

$3,706in general payments, 2019–2025

Across 179 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$933
  • GSK$388
  • Sanofi$319
  • Jazz Pharmaceuticals Inc.$278
  • Actelion Pharmaceuticals US, Inc.$265
  • Boehringer Ingelheim$251
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,706100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,706 in reported general payments places this provider in the 90th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$15,653
Medicare patients
97
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter360$296,052
Breztri AerosphereBudesonide/Glycopyr/Formoterol176$135,609
Spiriva RespimatTiotropium Bromide78$56,588
Dupixent PenDupilumab14$52,389
Stiolto RespimatTiotropium Br/Olodaterol Hcl41$37,095
DuleraMometasone/Formoterol64$30,374
Advair HfaFluticasone Propion/Salmeterol61$27,486
EliquisApixaban30$21,790
Breo ElliptaFluticasone/Vilanterol47$20,467
Albuterol Sulfate HfaAlbuterol Sulfate545$15,961
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$15,847
SymbicortBudesonide/Formoterol Fumarate43$15,268
Incruse ElliptaUmeclidinium Bromide36$14,208
Bevespi AerosphereGlycopyrrolate/Formoterol Fum30$13,128
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$6,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$388$346,574467 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$933$164,006249 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$251$93,684119 claims
MerckDulera$15$30,37464 claims
PfizerEliquis$69$21,79030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →